Mouse PDX Trial Suggests Synergy of Concurrent Inhibition of RAF and EGFR in Colorectal Cancer with or Mutations.

To evaluate the antitumor efficacy of cetuximab in combination with LSN3074753, an analog of LY3009120 and pan-RAF inhibitor in 79 colorectal cancer patient-derived xenograft (PDX) models. Seventy-nine well-characterized colorectal cancer PDX models were employed to conduct a single mouse per treatment group ( = 1) trial. Consistent with clinical results, cetuximab was efficacious in wild-type and PDX models, with an overall response rate of 6.